If data can throw your biotherapeutic development program into chaos, it can also help move you forward. Let’s see how.
The improvements in LC-MS technology under GxP compliant-ready informatics for biopharmaceutical analysis has prepared the industry to expand the role of MS technologies beyond product characterization toward monitoring product and process quality attributes.
You won’t like what we found when we tested skin lightening cosmetics that we purchased online.
Choosing the right technology is crucial – so it’s great when innovation makes the decision clear-cut. With Gerard Rosse, Associate Director, Structure Guided Chemistry at Dart NeuroScience.
What are the challenges when translating complexity into simplicity – and how do we measure success in such an endeavor? Daniel Kenny, Director of MS Development at Waters, shares the motivation, inspiration and celebration behind… Read more >
With access to multiple mass spectrometry systems of varying degrees of sophistication, Davy Guillarme (University of Geneva, Switzerland) wasn’t actively looking for new mass detection solutions. Nevertheless, the Waters ACQUITY QDa mass detector caught his eye.
At Reach Separations, they’re putting robust detection on the front lines of method development and mass confirmation.
How mass detection allows us to tell the beautiful truth about beer By Larissa Burns, Group Technical Analyst, Lion Co. I’ve been working at Lion as their analytical specialist for eight years, predominantly using… Read more >
The quality issues of biopharmaceutical therapeutics are definitely different from chemical drugs because of the increased complexity of manufacturing processes and complexity of the biologic molecules themselves. There is an increasing need for detailed product… Read more >
As regulators focus in on the critical quality attributes (CQAs) of biotherapeutics, what can biopharmaceutical labs in late development or QC do to increase confidence in their bioseparations assays – other than to run additional… Read more >